35 completed, 3 active not recruiting, 2 recruiting, 1 unknown. 42 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 42 | Completed 35, Active not recruiting 3, Recruiting 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 1, Recruiting 1, Unknown 1, Withdrawn 1 |
Follow Tamsulosin: new trials by email Literature Review of Tamsulosin trials Research Report on Tamsulosin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets, in Healthy Adult Male Subjects, Under Fasting Conditions Tamsulosin (0.4 mg/j) - Healthy Volunteer Male Subjects | Phase 1 | Recruiting | Berlin-Chemie AG Menarini Group | 46 | 2025-09-08 | 2025-10-03 |
| A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin 0.4 mg Tablets, in Healthy Adult Male Subjects, Under Fed Conditions Tamsulosin (0.4 mg/j) - Healthy Volunteers, Male | Phase 1 | Active not recruiting | Berlin-Chemie AG Menarini Group | 46 | 2025-06-16 | 2025-08-08 |
| A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady State Tamsulosin (0.4 mg/j), Omnic Ocas®, - Healthy Adult Males Volunteers | Phase 1 | Active not recruiting | Berlin-Chemie AG Menarini Group | 33 | 2025-03-03 | 2025-08-28 |
| Bioequivalence Study of Tamsulosin 0.4 mg Sustained Release Film-coated Tablets Tamsulosin 0.4 mg Sustained Release Tablet (produced by PT Dexa Medica, Indonesia), Harnal® OCAS 0.4 mg Prolonged Release Tablet (produced by Astellas Pharma Europe B.V., The Netherlands, imported by PT Combiphar, Indonesia) - Healthy | Phase 1 | Completed | Dexa Medica Group | 28 | 2023-11-06 | 2024-08-16 |
| COMPARISON OF SILODOSIN AND TAMSULOSIN IN MEDICAL EXPULSIVE THERAPY OF DISTAL URETERIC CALCULI Silodosin, Tamsulosin - Silodosin, Tamsulosin, Medical Expulsive Therapy, Distal Ureteric Calculi | Phase 1 | Completed | Armed Forces Institute of Urology, Rawalpindi | 142 | 2022-09-01 | 2023-03-30 |
| A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers. BR9006-1, BR9006-2 - Benign Prostatic Hyperplasia (BPH), Overactive Bladder | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 36 | 2020-07-20 | 2020-10-28 |
| Prophylactic Administration of Alpha Blockers for Prevention of Urinary Retention in Males Undergoing Inguinal Hernia Repair Under Spinal Anaesthesia. Tamsulosin, Placebo oral tablet - Inguinal Hernia, Urinary Retention | Phase 1 / Phase 2 | Completed | Georgios Koukoulis | 100 | 2020-02-01 | 2021-11-26 |
| Post-operative Urinary Retention (POUR) Following Thoracic Surgery Tamsulosin - 1 week, Tamsulosin - 3 days - Urinary Retention | Phase 1 / Phase 2 | Recruiting | Hackensack Meridian Health | 127 | 2018-05-07 | 2026-06-11 |
| Evaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DME Bromocriptine 2.5 MG, Metoprolol 25 MG, Tamsulosin 0.4 MG - Diabetic Macular Edema | Phase 1 / Phase 2 | Withdrawn | Andrew Moshfeghi, MD, MBA | 2018-03-01 | 2019-04-01 | |
| A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer IGRT 45 Gy in 5 fractions of 9 Gy, IGRT 24 Gy single dose, Dexamethasone - Prostate Cancer | Phase 1 | Active not recruiting | Albert Einstein College of Medicine | 31 | 2016-08-01 | 2026-04-03 |
| The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers. JLP-1207, Solifenacin 5mg+Tamsulosin 0.2mg - LUTS(Lower Urinary Tract Symptoms), Benign Prostatic Hyperplasia | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 54 | 2015-08-01 | 2016-06-24 |
| Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet - Prostatic Hyperplasia | Phase 1 | Completed | GlaxoSmithKline | 56 | 2015-07-30 | 2018-06-19 |
| Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male. tamsulosin capsules, tamsulosin HCl - Prostatic Hyperplasia | Phase 1 | Completed | Boehringer Ingelheim | 34 | 2015-04-30 | 2020-04-27 |
| Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male. tamsulosin (Astellas), Tamsulosin HCL - Prostatic Hyperplasia | Phase 1 | Completed | Boehringer Ingelheim | 34 | 2015-04-01 | 2020-04-17 |
| CKD-397 Drug-drug Interaction Study (B) Harnal-D Cap. 0.2mg, Cialis Tab. 5mg - Healty Male Volunteers | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 29 | 2014-09-01 | 2015-08-20 |
| CKD-397 Drug-drug Interaction Study (A) Cialis Tab. 5mg, Harnal-D Cap. 0.2mg - Healthy | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 16 | 2014-09-01 | 2015-08-20 |
| Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin Tamsulosin, Solifenacin, Tamsulosin and solifenacin - LUTS, Benign Prostatic Hyperplasia | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 36 | 2014-07-01 | 2016-06-24 |
| Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects Mirabegron, Solifenacin succinate, Tamsulosin HCl - Healthy Subjects, Pharmacokinetics | Phase 1 | Completed | Astellas Pharma Europe B.V. | 20 | 2014-05-01 | 2014-08-29 |
| Evaluating a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin Tadalafil, Tamsulosin, Tadalafil + Tamsulosin - Erectile Dysfunction, Benign Prostatic Hyperplasia | Phase 1 | Completed | Hanmi Pharmaceutical Company Limited | 30 | 2014-03-01 | 2014-09-12 |
| Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted State Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg, Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule - Urologic Diseases | Phase 1 | Completed | GlaxoSmithKline | 78 | 2014-02-19 | 2018-09-13 |
Showing 20 of 42. Sign in to see all of them.
Prostatic Hyperplasia (14) · Urinary Bladder, Overactive (4) · Erectile Dysfunction (2) · Lower Urinary Tract Symptoms (2) · Urinary Retention (2) · Urologic Diseases (2) · Hernia, Inguinal (1) · Hypertension (1) · Lung Neoplasms (1) · Multiple System Atrophy (1) · Prostatic Neoplasms (1) · Pure Autonomic Failure (1) · Shy-Drager Syndrome (1) · Urinary Bladder Neck Obstruction (1) · Urinary Bladder, Neurogenic (1)
GlaxoSmithKline (8) · Boehringer Ingelheim (7) · Astellas Pharma Europe B.V. (4) · Berlin-Chemie AG Menarini Group (3) · Chong Kun Dang Pharmaceutical (2) · Jeil Pharmaceutical Co., Ltd. (2) · Teva Pharmaceuticals USA (2) · Albert Einstein College of Medicine (1) · Andrew Moshfeghi, MD, MBA (1) · Armed Forces Institute of Urology, Rawalpindi (1) · Astellas Pharma Inc (1) · Boryung Pharmaceutical Co., Ltd (1) · Dexa Medica Group (1) · GL Pharm Tech Corporation (1) · Georgios Koukoulis (1)
South Korea (7) · United Kingdom (5) · United States (5) · Armenia (3) · Australia (3) · Canada (2) · China (1) · Germany (1) · Greece (1) · Indonesia (1) · Netherlands (1) · Pakistan (1) · Russia (1)
Min Gul Kim, PhD (2) · Shougher Heboyan, MD (2) · An-Hye Kim (1) · Andrew A. Moshfeghi, MD, MBA (1) · Georgios D Koukoulis, MD, PhD (1) · Italo Biaggioni, MD (1) · Ji-Young Park, MD, PhD (1) · Konstantinos Mpouliaris, MD (1) · Konstantinos Tepetes, MD, PHD (1)
PMID 10851208, PMID 11927799, PMID 12119802, PMID 12923400, PMID 15738343, PMID 16391172, PMID 16533484, PMID 18426998, PMID 19047577, PMID 19738158, PMID 22801444, PMID 23266540, PMID 28800206, PMID 9369256, PMID 9890307
2009 (2)